In the current market session, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) is trading at $80.65, after a 5.06% drop. However, over the past month, the stock spiked by 5.06%, and in the past year, by 8.44%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 12.87%.

Most often, an industry will prevail in a particular phase of a business cycle, than other industries.

Biomarin Pharmaceutical Inc. has a lower P/E than the aggregate P/E of 32.33 of the Biotechnology industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued.

There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.